Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.22
REGN's Cash to Debt is ranked higher than
58% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. REGN: 1.22 )
REGN' s 10-Year Cash to Debt Range
Min: 0.57   Max: No Debt
Current: 1.22

Equity to Asset 0.68
REGN's Equity to Asset is ranked higher than
73% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. REGN: 0.68 )
REGN' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.93
Current: 0.68

0.18
0.93
Interest Coverage 16.37
REGN's Interest Coverage is ranked higher than
54% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 16.37 )
REGN' s 10-Year Interest Coverage Range
Min: 0.46   Max: 16.37
Current: 16.37

0.46
16.37
F-Score: 4
Z-Score: 19.33
M-Score: -2.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 36.11
REGN's Operating margin (%) is ranked higher than
97% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. REGN: 36.11 )
REGN' s 10-Year Operating margin (%) Range
Min: -554.63   Max: 187.97
Current: 36.11

-554.63
187.97
Net-margin (%) 20.16
REGN's Net-margin (%) is ranked higher than
93% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. REGN: 20.16 )
REGN' s 10-Year Net-margin (%) Range
Min: -565.66   Max: 54.43
Current: 20.16

-565.66
54.43
ROE (%) 21.74
REGN's ROE (%) is ranked higher than
96% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. REGN: 21.74 )
REGN' s 10-Year ROE (%) Range
Min: -85.2   Max: 60.24
Current: 21.74

-85.2
60.24
ROA (%) 14.38
REGN's ROA (%) is ranked higher than
96% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. REGN: 14.38 )
REGN' s 10-Year ROA (%) Range
Min: -31.76   Max: 36.06
Current: 14.38

-31.76
36.06
ROC (Joel Greenblatt) (%) 57.06
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. REGN: 57.06 )
REGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -218.13   Max: 197.42
Current: 57.06

-218.13
197.42
Revenue Growth (%) 50.60
REGN's Revenue Growth (%) is ranked higher than
96% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. REGN: 50.60 )
REGN' s 10-Year Revenue Growth (%) Range
Min: -25.3   Max: 81.3
Current: 50.6

-25.3
81.3
» REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

REGN Guru Trades in Q3 2013

Joel Greenblatt 3,285 sh (New)
Frank Sands 3,777,357 sh (+20.34%)
Jim Simons 249,521 sh (+6.29%)
Vanguard Health Care Fund 1,412,100 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Jeremy Grantham Sold Out
Steven Cohen 1,420 sh (-95.72%)
» More
Q4 2013

REGN Guru Trades in Q4 2013

Steven Cohen 28,304 sh (+1893.24%)
Vanguard Health Care Fund 1,412,100 sh (unchged)
Joel Greenblatt Sold Out
Frank Sands 3,732,680 sh (-1.18%)
Jim Simons 70,062 sh (-71.92%)
» More
Q1 2014

REGN Guru Trades in Q1 2014

Andreas Halvorsen 1,051,800 sh (New)
Paul Tudor Jones 893 sh (New)
Ron Baron 6,084 sh (New)
Steven Cohen 65,232 sh (+130.47%)
Vanguard Health Care Fund 1,743,468 sh (+23.47%)
Frank Sands 4,012,062 sh (+7.48%)
Jim Simons Sold Out
» More
Q2 2014

REGN Guru Trades in Q2 2014

Vanguard Health Care Fund 2,795,500 sh (+60.34%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-06-30 Add 60.34%0.79%$277.29 - $313.74 $ 324.319%2795500
Vanguard Health Care Fund 2014-03-31 Add 23.47%0.29%$267.62 - $347.62 $ 324.316%1743468
Frank Sands 2014-03-31 Add 7.48%0.22%$267.62 - $347.62 $ 324.316%4012062
Ron Baron 2014-03-31 New Buy0.01%$267.62 - $347.62 $ 324.316%6084
Joel Greenblatt 2013-12-31 Sold Out 0.03%$261.88 - $313.67 $ 324.3113%0
Frank Sands 2013-09-30 Add 20.34%0.56%$227.65 - $309.174 $ 324.3123%3777357
Joel Greenblatt 2013-09-30 New Buy0.03%$227.65 - $309.174 $ 324.3123%3285
Ray Dalio 2013-09-30 Sold Out 0.01%$227.65 - $309.174 $ 324.3123%0
Frank Sands 2013-06-30 Add 81.03%1.07%$178.51 - $282.8 $ 324.3139%3138793
Ray Dalio 2013-06-30 New Buy0.01%$178.51 - $282.8 $ 324.3139%4100
Frank Sands 2013-03-31 Reduce -46.22%1.02%$158.42 - $183.77 $ 324.3189%1733896
Vanguard Health Care Fund 2013-03-31 Add 170.41%0.62%$158.42 - $183.77 $ 324.3189%1412100
Frank Sands 2012-09-30 Reduce -37.57%1.2%$112.77 - $152.66 $ 324.31140%3834373
Vanguard Health Care Fund 2012-09-30 Reduce -24.56%0.09%$112.77 - $152.66 $ 324.31140%522200
Frank Sands 2012-06-30 Add 6.5%0.2%$108.78 - $143.87 $ 324.31159%6142048
Dodge & Cox 2012-03-31 Sold Out $57.83 - $119.96 $ 324.31252%0
Carl Icahn 2011-09-30 Sold Out 1.76%$44.96 - $72.19 $ 324.31453%0
Dodge & Cox 2011-09-30 Reduce -97.62%0.03%$44.96 - $72.19 $ 324.31453%9400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA
According to GuruFocus Insider Data, the largest insider sells during the past week were: Microsoft Corp, Regeneron Pharmaceuticals Inc., Activision Blizzard Inc. and Mid-America Apartment Communities. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 89.90
REGN's P/E(ttm) is ranked higher than
86% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 89.90 )
REGN' s 10-Year P/E(ttm) Range
Min: 9.83   Max: 91.55
Current: 89.9

9.83
91.55
P/B 15.00
REGN's P/B is ranked higher than
59% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. REGN: 15.00 )
REGN' s 10-Year P/B Range
Min: 1.43   Max: 26.42
Current: 15

1.43
26.42
P/S 15.80
REGN's P/S is ranked higher than
74% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. REGN: 15.80 )
REGN' s 10-Year P/S Range
Min: 2.06   Max: 27.97
Current: 15.8

2.06
27.97
PFCF 96.30
REGN's PFCF is ranked higher than
90% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 96.30 )
REGN' s 10-Year PFCF Range
Min: 9.29   Max: 2102
Current: 96.3

9.29
2102
EV-to-EBIT 38.12
REGN's EV-to-EBIT is ranked higher than
89% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 38.12 )
REGN' s 10-Year EV-to-EBIT Range
Min: 4   Max: 2827.2
Current: 38.12

4
2827.2
PEG 36.80
REGN's PEG is ranked higher than
92% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 36.80 )
REGN' s 10-Year PEG Range
Min: 11.75   Max: 36.8
Current: 36.8

11.75
36.8
Shiller P/E 389.90
REGN's Shiller P/E is ranked higher than
91% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 389.90 )
REGN' s 10-Year Shiller P/E Range
Min: 334.08   Max: 1446.63
Current: 389.9

334.08
1446.63
Current Ratio 6.13
REGN's Current Ratio is ranked higher than
81% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. REGN: 6.13 )
REGN' s 10-Year Current Ratio Range
Min: 2.17   Max: 20.69
Current: 6.13

2.17
20.69
Quick Ratio 5.85
REGN's Quick Ratio is ranked higher than
81% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. REGN: 5.85 )
REGN' s 10-Year Quick Ratio Range
Min: 2.17   Max: 20.5
Current: 5.85

2.17
20.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 76.50
REGN's Price/Net Current Asset Value is ranked higher than
71% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. REGN: 76.50 )
REGN' s 10-Year Price/Net Current Asset Value Range
Min: 3.18   Max: 2443.86
Current: 76.5

3.18
2443.86
Price/Tangible Book 14.80
REGN's Price/Tangible Book is ranked higher than
65% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. REGN: 14.80 )
REGN' s 10-Year Price/Tangible Book Range
Min: 0.86   Max: 22
Current: 14.8

0.86
22
Price/DCF (Projected) 27.50
REGN's Price/DCF (Projected) is ranked higher than
89% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 27.50 )
REGN' s 10-Year Price/DCF (Projected) Range
Min: 14.99   Max: 240.67
Current: 27.5

14.99
240.67
Price/Median PS Value 1.50
REGN's Price/Median PS Value is ranked higher than
76% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. REGN: 1.50 )
REGN' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 5.06
Current: 1.5

0.21
5.06
Price/Graham Number 7.40
REGN's Price/Graham Number is ranked higher than
87% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 7.40 )
REGN' s 10-Year Price/Graham Number Range
Min: 1.24   Max: 7.27
Current: 7.4

1.24
7.27
Earnings Yield (Greenblatt) 2.40
REGN's Earnings Yield (Greenblatt) is ranked higher than
56% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. REGN: 2.40 )
REGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 24.9
Current: 2.4

1.3
24.9
Forward Rate of Return (Yacktman) -0.35
REGN's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. REGN: -0.35 )
REGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.8   Max: -0.4
Current: -0.35

-22.8
-0.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Regeneron Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The Company was incorporated in January 1988 in the State of New York. The Company currently has two marketed products: EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, which is available in the United States for the treatment of neovascular age-related macular degeneration (wet AMD). Wet AMD is the main cause of acquired blindness for people over the age of 65 in the United States and Europe; and ARCALYST (rilonacept) Injection for Subcutaneous Use, which is available by prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. The Company has 13 product candidates in clinical development, all of which were discovered in its research laboratories. Its Trap-based, late-stage programs are: EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as VEGF Trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment. The Company, together with its ex-U.S. collaborator Bayer HealthCare, is evaluating EYLEA in Phase 3 programs in patients with central retinal vein occlusion (CRVO), diabetic macular edema (DME), and choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The Company's manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 395,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 54,000 liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. The Company's competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current an
» More Articles for REGN

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
Insiders Are Buying Ophthotech Oct 08 2013 
Weekly Top Insider Sells: REGN May 27 2013 
comment on REGN Mar 06 2013 
Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price Sep 08 2012 
52-Week High Companies: BAM, REGN, TRV, WFC Aug 20 2012 
52-Week High Companies: EC, MAT, ORLY, V, REGN Apr 16 2012 
Weekly Top Insider Sells: TJX, MON, REGN, and PNC Jan 16 2012 


More From Other Websites
Massive, unusual options volume Friday confounds Wall St Aug 01 2014
Unusual options volume seen in Priceline, Regeneron, others Aug 01 2014
3 Stocks Pushing The Drugs Industry Higher Aug 01 2014
Watch For Today's Momo Momentum Stock: Regeneron Pharmaceuticals (REGN) Aug 01 2014
Len Schleifer's Science Focus Pays Off At Regeneron Jul 31 2014
[$$] Regeneron Boosted by Latest Approval Jul 31 2014
Sanofi lifts 2014 profit forecast as Q2 beats expectations Jul 31 2014
Sanofi lifts 2014 guidance after second quarter earnings beat expectations Jul 31 2014
Sanofi lifts 2014 guidance after Q2 earnings beat expectations Jul 31 2014
[$$] Drug Firms Buy $67.5 Million Voucher to Speed FDA Review Jul 31 2014
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission Jul 30 2014
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema Jul 30 2014
Sanofi, Regeneron cholesterol drug may cut heart risk, trial hints Jul 30 2014
Stocks End Mixed; Akamai Falls, Yelp Rises After Hours Jul 30 2014
US STOCKS-S&P 500, Nasdaq end up as Fed in no rush to raise rates Jul 30 2014
US STOCKS-S&P 500, Nasdaq end up as Fed in no rush to raise rates Jul 30 2014
4:05 pm Regeneron Pharms and Sanofi (SNY) announce plan to use... Jul 30 2014
Sanofi and Regeneron Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission Jul 30 2014
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission Jul 30 2014
US STOCKS-S&P 500 nearly flat as investors digest Fed statement Jul 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide